Aurobindo Pharma Ltd.
AUROPHARMA · ISIN: INE406A01037
Aurobindo Pharma Ltd. is a mid cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE406A01037.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
Constituent of NIFTY 500 TRI (0.24%), NIFTY LMC 250 TRI (0.57%), NIFTY MC 150 TRI (1.15%)
CHART
Aurobindo Pharma Ltd. - growth of ₹100
Growth of ₹100 invested on 2021-11-30, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-0.72%
3M
+5.04%
6M
+19.46%
1Y
+52.99%
3Y CAGR
+25.02%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Aurobindo Pharma Ltd. - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-06-30.
F&O Sentiment
Nearest expiry: 2026-11-23 · As of 2026-10-28.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-10-22 | SHORT_SELL | 2 |
| 2026-10-07 | SHORT_SELL | 41 |
| 2026-10-05 | SHORT_SELL | 41 |
| 2026-09-30 | SHORT_SELL | 4,150 |
| 2026-09-29 | SHORT_SELL | 11,539 |
| 2026-09-21 | SHORT_SELL | 200 |
| 2026-09-15 | SHORT_SELL | 1,860 |
| 2026-09-10 | SHORT_SELL | 369 |
| 2026-09-09 | SHORT_SELL | 25 |
| 2026-09-08 | SHORT_SELL | 10 |
| 2026-08-25 | SHORT_SELL | 1,100 |
| 2026-08-10 | SHORT_SELL | 2 |
| 2026-08-07 | SHORT_SELL | 8 |
| 2026-08-05 | SHORT_SELL | 100 |
Frequently asked questions
What is Aurobindo Pharma Ltd.'s 1-year and 3-year return?
Aurobindo Pharma Ltd.'s 1-year price return is +52.99%. Its 3-year CAGR (annualized return) is +25.02%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Aurobindo Pharma Ltd.'s latest financial performance?
Aurobindo Pharma Ltd.'s trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹34,935 Cr, with a TTM profit after tax of ₹3,711 Cr and an EBITDA margin of 16.63%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹64, with a 5-year EPS growth rate of 3.32% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is Aurobindo Pharma Ltd.'s quality score?
Aurobindo Pharma Ltd. has a Punji quality score of 72.7 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Aurobindo Pharma Ltd.'s technical indicators show?
As of 2026-10-29, Aurobindo Pharma Ltd.'s RSI (14-day) is 51.65 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Aurobindo Pharma Ltd.?
As of 2026-06-30, Aurobindo Pharma Ltd.'s shareholding is split across Promoter (51.88%), Public (48.12%). Promoter holding of 51.88% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Is Aurobindo Pharma Ltd. part of any major market index?
Yes - Aurobindo Pharma Ltd. is a constituent of NIFTY 500 TRI (0.24% weight) and NIFTY LMC 250 TRI (0.57% weight) and NIFTY MC 150 TRI (1.15% weight). Index membership means the stock is automatically bought by every index fund and ETF tracking that benchmark, in proportion to its weight, which brings a baseline level of passive-fund demand independent of active investor sentiment. A stock's weight in an index is typically determined by its free-float market capitalization relative to the index's other constituents, and is periodically rebalanced as relative market caps shift.
What does the F&O market show for Aurobindo Pharma Ltd.?
As of 2026-10-28 (nearest expiry 2026-11-23), Aurobindo Pharma Ltd.'s put-call ratio by open interest is 0.6336 - below 1, typically read as bullish positioning (more open interest on calls than puts). The max pain strike is ₹1600, the price at which option writers as a group would owe the least to option buyers at expiry - a reference level some traders watch, not a price target. F&O positioning reflects derivatives-market sentiment over a specific expiry window, not a fundamental view on the company.
Has Aurobindo Pharma Ltd. seen any recent bulk or block deals?
Yes, as of 2026-10-22 - the most recent recorded deal was a SHORT_SELL on 2026-10-22 for 2 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
Stock data · Not financial advice · Past performance does not indicate future returns